Imugene (ASX:IMU) ROE % Adjusted to Book Value : -17.57% (As of Dec. 2023)

View and export this data going back to 1993. Start your Free Trial

What is Imugene ROE % Adjusted to Book Value?

Imugene's ROE % for the quarter that ended in Dec. 2023 was -71.49%. Imugene's PB Ratio for the quarter that ended in Dec. 2023 was 4.07. Imugene's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 was -17.57%.

Imugene ROE % Adjusted to Book Value Historical Data

The historical data trend for Imugene's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Imugene ROE % Adjusted to Book Value Chart

Imugene Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

-14.54

-10.92

-1.08

-4.96

-7.62

Imugene Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															-1.78	-4.23	-4.44	-6.83	-17.57

Competitive Comparison of Imugene's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Imugene's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Imugene's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Imugene's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Imugene's ROE % Adjusted to Book Value falls into.

Imugene ROE % Adjusted to Book Value Calculation

Imugene's ROE % Adjusted to Book Value for the fiscal year that ended in Jun. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-23.10%	/	3.03
	=	-7.62%

Imugene's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-71.49%	/	4.07
	=	-17.57%

Imugene ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Imugene's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Imugene (ASX:IMU) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Imugene Ltd (ASX:IMU) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

IUGNF:USA

Address

4-6 Bligh Street, Suite 12.01, Level 12, Sydney, NSW, AUS, 2000

Website

https://www.imugene.com

Imugene Ltd specializes in a clinical-stage immuno-oncology company. Its product includes HER-Vaxx,PD1-Vaxx, CF33 and CF33 CD19. HER-Vaxx is a proprietary HER2 +ve cancer vaccine that stimulates a polyclonal antibody response to HER2/neu. The company is also developing B-cell peptide cancer vaccines and therapeutics. Its only operating segment being the Research and Development of oncolytic immunotherapies.

Imugene (ASX:IMU) Headlines

No Headlines